Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rassidakis, G. Z.
Right arrow Articles by Medeiros, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rassidakis, G. Z.
Right arrow Articles by Medeiros, L. J.
Clinical Cancer Research Vol. 9, 1121-1128, March 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Expression of p27Kip1 and c-Jun Activation Binding Protein 1 Are Inversely Correlated in Systemic Anaplastic Large Cell Lymphoma1

George Z. Rassidakis, Francois-Xavier Claret, Raymond Lai, Qingxiu Zhang, Andreas H. Sarris, Timothy J. McDonnell and L. Jeffrey Medeiros2

Departments of Hematopathology [G. Z. R., R. L., L. J. M.], Molecular Therapeutics [F-X. C., Q. Z.], Lymphoma-Myeloma [A. H. S.], and Molecular Pathology [T. J. M.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Purpose: p27Kip1(p27) is a universal cyclin-dependent kinase inhibitor that inhibits cell cycle transition from G1 to S phase and is primarily regulated at the post-transcriptional level via the ubiquitin-proteasome pathway. In vitro data suggest that p27 degradation may be accelerated by the c-Jun activation domain binding protein-1 (JAB1), originally identified as a coactivator of the gene regulatory AP-1 proteins. We assessed p27 and JAB1 in systemic anaplastic large cell lymphoma (ALCL), a group of tumors in which a substantial subset overexpresses anaplastic lymphoma kinase (ALK).

Experimental Design: The study included 5 ALK-positive ALCL cell lines, namely Karpas 299, JB-6, SR-786, SU-DHL1, and TG-S1, and 66 ALCL tumors (24 ALK positive and 42 ALK negative). The cell lines were analyzed by Western blot methods, and the tumors were assessed immunohistochemically.

Results: SU-DHL1 and TG-S1 cells were positive for p27 and negative for JAB1, whereas SR-786 and JB-6 cells were positive for JAB-1 but negative for p27. Karpas 299 expressed p27 at relatively low levels and JAB1 at high levels. Using a 10% cutoff, p27 was positive in 12 of 66 (18.2%) ALCL tumors (5 ALK positive and 7 ALK negative), whereas JAB1 was detected in 47 of 53 (88.7%) tumors (15 ALK positive and 32 ALK negative) assessed. p27 and JAB1 expression were inversely correlated (Spearman r = -0.27, P = 0.03). For 54 ALCL patients with complete follow-up, and in separate analyses of patients with ALK-positive or -negative tumors, p27 expression correlated with poorer prognosis.

Conclusions: p27 is absent or expressed at low levels in most ALCL tumors and inversely correlates with JAB1. These findings suggest that JAB1-mediated degradation of p27, allowing cell cycle progression, may play a role in the pathogenesis of ALCL.




This article has been cited by other articles:


Home page
BloodHome page
H. M. Amin and R. Lai
Pathobiology of ALK+ anaplastic large-cell lymphoma
Blood, October 1, 2007; 110(7): 2259 - 2267.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Leventaki, E. Drakos, L. J. Medeiros, M. S. Lim, K. S. Elenitoba-Johnson, F. X. Claret, and G. Z. Rassidakis
NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma
Blood, September 1, 2007; 110(5): 1621 - 1630.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. A. Kouvaraki, A. L. Korapati, G. Z. Rassidakis, L. Tian, Q. Zhang, P. Chiao, L. Ho, D. B. Evans, and F. X. Claret
Potential Role of Jun Activation Domain-Binding Protein 1 as a Negative Regulator of p27kip1 in Pancreatic Adenocarcinoma.
Cancer Res., September 1, 2006; 66(17): 8581 - 8589.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Vega, L. J. Medeiros, V. Leventaki, C. Atwell, J. H. Cho-Vega, L. Tian, F.-X. Claret, and G. Z. Rassidakis
Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma.
Cancer Res., July 1, 2006; 66(13): 6589 - 6597.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. P. Oyarzo, L. J. Medeiros, C. Atwell, M. Feretzaki, V. Leventaki, E. Drakos, H. M. Amin, and G. Z. Rassidakis
c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma
Blood, March 15, 2006; 107(6): 2544 - 2547.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Tomoda, J.-y. Kato, E. Tatsumi, T. Takahashi, Y. Matsuo, and N. Yoneda-Kato
The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression
Blood, January 15, 2005; 105(2): 775 - 783.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Z. Rassidakis, M. Feretzaki, C. Atwell, I. Grammatikakis, Q. Lin, R. Lai, F.-X. Claret, L. J. Medeiros, and H. M. Amin
Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma
Blood, January 15, 2005; 105(2): 827 - 829.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Tomoda, N. Yoneda-Kato, A. Fukumoto, S. Yamanaka, and J.-y. Kato
Multiple Functions of Jab1 Are Required for Early Embryonic Development and Growth Potential in Mice
J. Biol. Chem., October 8, 2004; 279(41): 43013 - 43018.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
G. Z. Rassidakis, R. Lai, M. Herling, C. Cromwell, A. Schmitt-Graeff, and L. J. Medeiros
Retinoblastoma Protein Is Frequently Absent or Phosphorylated in Anaplastic Large-Cell Lymphoma
Am. J. Pathol., June 1, 2004; 164(6): 2259 - 2267.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.